RxDoctor Payments Data

Maria Villasenor, MD

Family Medicine · Oxnard, CANPI 1114147402

Payments from drug & device makers

$762in general payments, 2019–2025

Across 25 payments — averaging $30.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • Astellas Pharma US Inc$198
  • Agios Pharmaceuticals, Inc.$54
  • Abbott$53
  • Amgen$50
  • Merck$46
  • plus $147 from 6 others

What the payments were for

  • Food & beverage$66387%
  • Education$9913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$32,479
Medicare patients
86
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$30,227
FarxigaDapagliflozin Propanediol17$17,455
MyrbetriqMirabegron19$15,112
JanuviaSitagliptin Phosphate14$9,611
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,390
Lidocaine12$1,257
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$1,169
Atorvastatin Calcium158$919
Escitalopram Oxalate84$686
Levothyroxine Sodium101$589
Omeprazole78$585
Ibandronate Sodium16$568
Metformin Hcl111$520
Amlodipine Besylate145$518
Losartan Potassium68$495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$33$17,45517 claims
Astellas Pharma US IncMyrbetriq$198$15,11219 claims
MerckJanuvia$46$9,61114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →